PUBLISHER: Value Market Research | PRODUCT CODE: 1332696
PUBLISHER: Value Market Research | PRODUCT CODE: 1332696
The global demand for PET Radiotracer Market is presumed to reach the market size of nearly USD 6.4 BN by 2030 from USD 3.17 BN in 2022 with a CAGR of 9.2% under the study period 2023 - 2030.
A PET radiotracer, also known as a PET radiopharmaceutical or PET tracer, is a radioactive compound used in Positron Emission Tomography (PET) imaging.It is a nuclear imaging technique that provides detailed images of the physiological and biochemical processes in the body.
The increasing prevalence of cancer worldwide fuels the demand for PET imaging with radiotracers, which assist in cancer diagnosis and treatment evaluation. Advancements in molecular imaging and the development of new radiotracers expand the capabilities of PET imaging, making it applicable to various medical fields and physiological processes. The emphasis on early disease detection and personalized medicine further drives the demand for PET radiotracers. Research and development efforts in nuclear medicine result in the discovery of novel radiotracers, enhancing the availability and application of PET imaging. Increased funding, investments, and government support boost the commercialization and adoption of PET radiotracers. The growing ageing population contributes to the demand for PET imaging in age-related diseases, such as cancer and neurodegenerative disorders. PET radiotracers are also essential in drug development and clinical trials, assessing drug efficacy and target engagement. Favourable reimbursement policies and the integration of PET with other imaging modalities further support the growth of the PET radiotracer market.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pet radiotracer. The growth and trends of pet radiotracer industry provide a holistic approach to this study.
This section of the pet radiotracer market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the PET Radiotracer market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the PET Radiotracer market include ABX Advanced Biochemical Compounds GmbH (Cambridge Isotope Laboratories Inc.), Blue Earth Diagnostics, Cardinal Health., Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions, Jubilant Pharma Limited, Lantheus Holdings Inc., Siemens Healthineers AG, Yantai Dungcheng Pharmaceutical Group Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.